CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating

Negative
AI Analysis

Summary

UBS reduced its price target on Syndax Pharmaceuticals from $37 to $33 while maintaining a Buy rating.

Importance:2/10
Sentiment:
-0.30
price_target_reductionanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on August 21, 2026 12:26 PM

Read Original